Cyclo Therapeutics News

Express News | Cyclo Therapeutics Q1 2024 GAAP EPS $(0.15) Beats $(0.19) Estimate, Sales $202.450K Miss $376.667K Estimate

Benzinga30minutes ago

Cyclo Therapeutics Ends 1Q With About $2.9M Cash>CYTH

Cyclo Therapeutics Ends 1Q With About $2.9M Cash>CYTH

Dow Jones53minutes ago

Cyclo Therapeutics 1Q Research and Development Expenses Fell 16% to $2.8M >CYTH

Cyclo Therapeutics 1Q Research and Development Expenses Fell 16% to $2.8M >CYTH

Dow Jones53minutes ago

Express News | Cyclo Therapeutics Q1 Net Income USD -4.3 Million

Reuters54minutes ago

Cyclo Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

GAINESVILLE, Fla. – Cyclo Therapeutics, Inc. (Nasdaq: CYTH) ("Cyclo Therapeutics" or the "Company"), a clinical stage biotechnology company dedicated to developing life-changing medicines through scie

Cyclo Therapeutics00:00 ET

10-Q: Quarterly report

SEC announcement16:07 ET · Announcements

Niemann-Pick Disease Type C Market Insight, Epidemiology and Market Forecast - 2032, Featuring Zevra Therapeutics, Azafaros, Cyclo Therapeutics and IntraBio

Yahoo FinanceMay 6 04:08 ET

Cyclo Therapeutics Initiated at Buy by HC Wainwright & Co.

Cyclo Therapeutics Initiated at Buy by HC Wainwright & Co.

Dow JonesMay 1 06:23 ET

Analysts Are Bullish on These Healthcare Stocks: Exelixis (EXEL), Cyclo Therapeutics (CYTH)

TipRanksMay 1 06:17 ET

Express News | Cyclo Therapeutics, Inc. : H.c. Wainwright Initiates Coverage With Buy Rating and Target Price $3

ReutersMay 1 06:06 ET

Cyclo Therapeutics Initiated at Buy by Ascendiant Capital

Cyclo Therapeutics Initiated at Buy by Ascendiant Capital

Dow JonesApr 22 05:47 ET

Express News | Ascendiant Capital Initiates Coverage On Cyclo Therapeutics With Buy Rating, Announces Price Target of $2.6

Moomoo 24/7Apr 22 05:40 ET

Cyclo Therapeutics Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/22/2024 124.14% Ascendiant Capital → $2.6 Initiates Coverage On → Buy 09/27/2023 244.83% Maxim Group →

BenzingaApr 22 05:35 ET

Analysts Offer Insights on Healthcare Companies: Cyclo Therapeutics (CYTH), CytomX Therapeutics (CTMX) and Pacific Biosciences (PACB)

TipRanksApr 22 04:20 ET

12 Health Care Stocks Moving In Thursday's After-Market Session

GainersBio-Path Hldgs (NASDAQ:BPTH) stock moved upwards by 9.0% to $4.58 during Thursday's after-market session. The company's market cap stands at $3.4 million. Biora Therapeutics (NASDAQ:BIOR) share

BenzingaApr 18 16:31 ET

12 Health Care Stocks Moving In Tuesday's After-Market Session

GainersOneMedNet (NASDAQ:ONMD) shares moved upwards by 75.9% to $1.39 during Tuesday's after-market session. The market value of their outstanding shares is at $44.8 million. Aesthetic Medical Intl (N

BenzingaApr 2 16:31 ET

Express News | Cyclo Therapeutics Receives Decision To Grant European Patent Titled 'METHODS FOR TREATING ALZHEIMER'S DISEASE WITH HP-[BETA]-CYCLODEXTRIN'

Moomoo 24/7Apr 2 14:31 ET

Buy Rating Affirmed for Cyclo Therapeutics on Strong Clinical and Financial Prospects

TipRanksMar 19 15:35 ET

Express News | Cyclo Therapeutics FY23 EPS $(1.23) Up From $(1.83) YoY; Revenue $1.076M Down From $1.375M YoY

Moomoo 24/7Mar 18 09:11 ET

Press Release: Cyclo Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update

Cyclo Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update Continued progress of pivotal Phase 3 study (TransportNPC(TM)) evaluating Trappsol(R) Cyclo(TM) for the treatm

Dow JonesMar 18 09:05 ET